Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective real-world study of Luxturna in RPE65-associated inherited retinal degeneration
NL-OMON50929Recruiting
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Mar 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of voretigene neparvovec in RPE65-associated inherited retinal degeneration (RPE65-IRD), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Full-field stimulus testing. Started Mar 2021; status: recruiting.
02
Drugs
voretigene neparvovec
03
Conditions
RPE65-associated inherited retinal degeneration (RPE65-IRD)
Beyond the preview
Go deeper on NL-OMON50929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50929.